Renal Cell Carcinoma

Elizabeth Plimack, MD, discusses the 2-year updated data from the CheckMate-025 trial in RCC, as well as the remaining questions with nivolumab in this setting.

In the treatment of patients with renal cell carcinoma, there has been a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors.

Tian Zhang, MD, discusses the challenges associated with vaccine development in kidney cancer and the hope that vaccines can still be the answer to improving the response rates with anti¬–PD-1/PD-L1 treatment in RCC.

Supporting the concept of post-progression survival and the influence of different patterns of progression, a new analysis showed patients with advanced HCC had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression.

Thomas E. Hutson, DO, PharmD, discusses the power of the lenvatinib/everolimus combination and how and when the regimen should be used in patients with advanced renal cell carcinoma. 

Chung-Han (Joe) Lee, MD, discusses recent treatment approvals in RCC, current and emerging treatments and strategies, and the significance of clinical trial enrollment.

A supplemental new drug application (sNDA) for the use of regorafenib (Stivarga) as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) has been granted priority review by the FDA.

James J. Hsieh, MD,&nbsp;discusses differential overall survival (OS) results of the RECORD-3 study based on 3 distinct mRCC molecular subgroups, classified by patients who harbored <em>BAP1</em> and/or <em>PBRM1</em> mutations.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

Among the new agents currently being explored in clinical trials, NKTR-214 stands out as a new cytokine therapy approach that could show additive benefit when combined with checkpoint inhibitors.&nbsp;

David F. McDermott, MD, discusses methods of expanding on progress seen in the field of immunotherapy, both in the case of kidney cancer and other tumor types at the PER&reg; European Congress on Immunotherapies in Cancer held in Barcelona.

Toni Choueiri, MD, discusses some of the ongoing clinical trials in metastatic renal cell carcinoma (mRCC).

Robert S. Alter, MD discusses optimal sequencing for bladder cancer agents and how he determines the appropriate treatment for patients.

Toni Choueiri, MD, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).

Elizabeth Plimack, MD, discusses recent pivotal findings in the field of genitourinary malignancies, specifically renal cell carcinoma (RCC) and bladder cancer.

Cabozantinib (Cabometyx) reduced the risk of progression or death by 31% compared with sunitinib (Sutent) in the frontline setting for patients with metastatic renal cell carcinoma (RCC).

Adjuvant sunitinib (Sutent) prolonged disease-free survival (DFS) by 1.2 years compared with placebo following nephrectomy for patients with high-risk clear cell renal cell carcinoma (RCC).

Jeffrey Infante, MD, Director of Drug Development at Sarah Cannon, discusses findings of the AM0010 study.

James Hsieh, MD, PhD, discusses the 3 &quot;eras&quot; in the treatment of kidney cancer.

The European Commission (EC) has granted its approval for lenvatinib (Kisplyx; EU) in combination with everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC) following 1 prior VEGF-targeted therapy.

Across the fields of renal cell carcinoma, bladder cancer, and prostate cancer, immunotherapy agents are moving through the pipeline and impacting patient outcomes&mdash;some quicker than others.

Patients with renal cancer who underwent cytoreductive nephrectomy (CN) and targeted therapy (TT) had improved survival compared with patients who did not undergo the surgery, according to research from the Dana-Farber Cancer Institute and Brigham and Women&rsquo;s Hospital.¹&nbsp;Historically, only 3 in 10 such patients undergo the procedure.

Mark Ball, MD, chief urology resident, Johns Hopkins University School of Medicine, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti-PD-1 therapy in renal cell carcinoma.

Sunitinib extended disease-free survival versus placebo as an adjuvant therapy for patients with renal cell carcinoma at high risk of recurrence in the phase III S-TRAC trial.

Infusion with 19-28z chimeric antigen receptor (CAR) modified T-cells led to complete response (CR) rates of 77% to 90% and minimal residual disease (MRD)-CR rates of 68% to 70% in adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (B-ALL).